RESEARCH ARTICLE
A 51-Year Old Woman with Schnitzler Syndrome Treated with Canakinumab
Simon Francis Thomsen*, 1, Pernille Hurup Duhn2, Johannes Kristensen1
Article Information
Identifiers and Pagination:
Year: 2011Volume: 5
First Page: 31
Last Page: 32
Publisher ID: TODJ-5-31
DOI: 10.2174/1874372201105010031
Article History:
Received Date: 07/07/2011Revision Received Date: 18/10/2011
Acceptance Date: 27/10/2011
Electronic publication date: 13/12/2011
Collection year: 2011
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Schnitzler syndrome is a rare auto-inflammatory disorder characterized by urticarial skin rash, a monoclonal IgM component and at least two of the following findings: periodic fever, arthralgias or arthritis, bone pain, palpable lymph nodes, liver or spleen enlargement, elevated erythrocyte sedimentation rate, leukocytosis, and abnormal findings on bone morphologic investigations. We present the first case of Schnitzler syndrome successfully treated with Canakinumab, a novel anti-IL-1-beta monoclonal antibody.